Invesco
PSTX

Invesco’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Invesco’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-29,797
Closed -$286K – 3850
2024
Q4 		$286K Buy
29,797
+932
+3% +$4.86K ﹤0.01% 3425
2024
Q3 		$82.6K Sell
28,865
-824
-3% -$2.55K ﹤0.01% 3645
2024
Q2 		$86.7K Sell
29,689
-1,542
-5% -$4.22K ﹤0.01% 3771
2024
Q1 		$99.6K Sell
31,231
-1,155
-4% -$3.85K ﹤0.01% 3740
2023
Q4 		$109K Buy
32,386
+4,722
+17% +$12.2K ﹤0.01% 3675
2023
Q3 		$65.8K Buy
27,664
+64
+0.2% +$134 ﹤0.01% 3774
2023
Q2 		$48.6K Buy
+27,600
New +$70.5K ﹤0.01% 3820
2023
Q1 		– Sell
-290,349
Closed -$1.54M – 4022
2022
Q4 		$1.54M Buy
+290,349
New +$1.33M ﹤0.01% 2741
2021
Q4 		– Sell
-11,629
Closed -$85K – 4115
2021
Q3 		$85K Buy
11,629
+954
+9% +$8.19K ﹤0.01% 3962
2021
Q2 		$107K Buy
+10,675
New +$95.6K ﹤0.01% 3884

Other funds holding PSTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Invesco's PSTX Position: Q1 2025 in Review

Invesco sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 29,797 shares — an estimated $286K sold.

Invesco first reported a position in PSTX in Q2 2021 and held it in 10 quarters. The position peaked at $1.54M in Q4 2022. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

  • Invesco reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Invesco sold 29,797 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $286K.
  • Invesco first reported a position in Poseida Therapeutics, Inc. Common Stock in Q2 2021 and held it in 10 quarters.
  • Invesco's Poseida Therapeutics, Inc. Common Stock position peaked at $1.54M in Q4 2022.
  • 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Invesco's 13F filing for Q1 2025, filed 12 May 2025.